Table 1. Characteristics of Thirteen Studies Included in the Meta-Analysisa.
| Study Year | Study Design | Region | Language of Paper | Number of Patients | Male | Female | Reported Endpoints |
|---|---|---|---|---|---|---|---|
| Fang Li 2008 (21) | Retrospective cohort | China | Chinese | 143 | 112 | 31 | mortality, TBIL, ALT and HBVDNA |
| Liya Huo 2008 (10) | Retrospective cohort | China | Chinese | 44 | 33 | 11 | mortality, TBIL, ALT, PTA and HBVDNA |
| Qiheng Xu 2009 (22) | Retrospective cohort | China | Chinese | 116 | NA | NA | survival, HBVDNA and TBIL |
| Cuijun Peng 2010 (23) | Retrospective cohort | China | Chinese | 92 | 63 | 29 | mortality, TBIL, and PTA |
| Jinhua Hu 2010 (18) | RCT | China | Chinese | 218 | 155 | 63 | survival, HBVDNA and MELD score |
| Xiaomin Wang 2010 (20) | RCT | China | Chinese | 74 | 62 | 12 | mortality, HBVDNA, PTA and TBIL |
| Yaoli Cui 2010 (24) | Retrospective cohort | China | English | 67 | 6 | 61 | survival, recurrence , HBV DNA and MELD score |
| Hongbo Gao 2011 (25) | Retrospective cohort | China | Chinese | 183 | NA | NA | survival, TBIL, PTA and HBVDNA |
| Tianyan Chen 2012 (26) | Retrospective cohort | China | English | 72 | 56 | 16 | mortality , recurrence and HBVDNA |
| Zhiyong Yang 2012 (19) | RCT | China | Chinese | 40 | NA | NA | survival, HBVDNA and MELD score |
| Lei Fan 2013 (11) | RCT | China | Chinese | 120 | NA | NA | mortality, TBIL, ALT PTA and HBVDNA |
| Jing Lai 2013 (12) | Retrospective cohort | China | English | 182 | 163 | 19 | mortality, MELD score and YMDD mutations |
| Junshuai Wang 2014 (27) | Retrospective cohort | China | English | 198 | NA | NA | survival, MELD score and TPPM score |
a Abbreviations: TBIL, total bilirubin; ALT, alanine transaminase; PTA, prothrombin activity; RTC, randomized controlled trial.